guest ::
| Home > Publications database > Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases |
| Home > Publications database > Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases |
| Journal Article | FZJ-2016-06354 |
; ; ; ; ; ; ; ; ; ;
2016
Oxford Univ. Press
Oxford
This record in other databases: 
Please use a persistent id in citations: doi:10.1093/neuonc/now154
Abstract: Identifying patients with pseudoprogression, which is characterized by an initial increase of contrast-enhancing lesions that resolve or at least stabilize spontaneously on follow-up imaging without any treatment change, is critical for avoiding premature termination of potentially effective treatment. With the advent and success of checkpoint inhibitors such as ipilimumab, nivolumab, or pembrolizumab in particular, detecting pseudoprogression in patients with malignant melanoma has become a major challenge in clinical practice given a frequency as high as 7%–10% of cases.1,2 Diagnosing progressive disease and excluding pseudoprogression in melanoma metastases using the immune-related Response Criteria (irRC)2 require the initial increase of at least 25% in lesions load to be confirmed by follow-up imaging at least 4 weeks later.2 However, particularly for brain metastases from malignant melanoma, follow-up imaging might not be feasible for patients with clinical deterioration at the time of initial increase of lesions load. These patients might not be able to wait 4 weeks for a follow-up investigation to decide on
; Allianz-Lizenz / DFG ; Current Contents - Clinical Medicine ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz
; No Authors Fulltext ; SCOPUS ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection
|
The record appears in these collections: |
PDF
PDF (PDFA)